|
|
||||||||
From the Center for Neuroscience and Aging, The Burnham Institute, La Jolla, California.
| Abstract |
|---|
|
|
|---|
METHODS. NMDA (2200 nmol), SB203580 (0.210 nmol, an inhibitor of p38 MAP kinase), LY294002 (6 nmol, an inhibitor of PI-3 kinase), or control solution was injected into the vitreous of Long-Evans rats. To assess retinal ganglion cell (RGC) death quantitatively, we labeled RGCs retrogradely by injecting aminostilbamidine (FluoroGold) into the superior colliculus and subsequently counting fluorescently labeled RGCs in retinal wholemounts. Phosphorylation of p38 and Akt was assessed by immunoblot of whole retinal lysates, and activity was measured with in vitro kinase assays. To localize phospho-p38 and phospho-Akt, immunohistochemistry was performed. TUNEL staining coupled with morphologic assessment was performed to assess apoptotic cell death.
RESULTS. Intravitreous injection of more than 10 nmol NMDA induced RGC death. Before death, NMDA-stimulated retinas manifested increased phospho-p38 and phospho-Akt in the ganglion cell and inner nuclear layers. Subsequently, pyknotic, TUNEL-positive cells were also localized to these regions. SB203580 partially rescued RGCs, whereas LY294002 enhanced death of RGCs due to 10 nmol NMDA. SB203580 and LY294002 specifically inhibited the activity of p38 MAP kinase and Akt, respectively.
CONCLUSIONS. The p38 MAP kinase and PI-3 kinase-Akt pathways are involved in signal transduction after excessive stimulation of NMDA receptors in the retina. These inhibitor studies suggest that the p38 MAP kinase pathway is proapoptotic, whereas the PI-3 kinase-Akt pathway is antiapoptotic in RGC death induced by NMDA.
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptorsand by metabotropic receptors that are coupled to G-proteins.2 Among these receptors, NMDA receptors, which are activated by the coagonists NMDA (or glutamate) and glycine, are known to be predominantly involved in neuronal cell death in the retina and elsewhere in the brain.3 4 5 6 In fact, there are several reports that glutamate is involved in retinal diseases, including glaucoma,7 ischemia,8 9 10 and optic neuropathy.11 NMDA may also protect against death of immature neurons in vitro.12 13 14 In these events, glutamate is thought to play a role in development and innervation. However, it is not known whether these opposing effects of NMDA on neuronal death occur in adult neurons in vivo.
Mitogen-activated protein (MAP) kinases are serine-threonine kinases and play an instrumental role in signal transduction from the cell surface to the nucleus. p38 represents a group of enzymes in the MAP kinase family that are activated and phosphorylated on a Thr-Gly-Tyr motif by environmental stress, such as hyperosmolarity, exposure to UV radiation, proinflammatory cytokines, and endotoxin.15 p38 MAP kinase is thought to participate in one of the signaling pathways mediating apoptosis in several cell types in various species.16 17 18 19 Glutamate signaling through the NMDA receptor also induces phosphorylation and activation of MAP kinases in primary neuronal cultures.20 21 Regarding retinal neurons in these events, we previously reported the following: Axotomy of the optic nerve induces apoptotic death of retinal ganglion cells (RGCs) in vivo; p38 MAP kinase is activated and phosphorylated in RGCs after axotomy; inhibition of p38 rescues RGCs from death after axotomy; MK-801, an antagonist of NMDA receptors, attenuates activation of p38 after axotomy in vivo; MK-801 protects RGCs from death after axotomy in vivo; and inhibition of p38 activity protects cultured RGCs from NMDA-induced apoptosis in vitro.22
Conversely, a number of factors in the survival of retinal and nonretinal neurons have been identified, including serum, insulin-like growth factor-1, and neurotrophins.14 23 24 25 26 27 28 29 These factors activate the phosphatidylinositol-3 (PI-3) kinase pathway, which is one of several signal transduction pathways implicated in the survival of neurons. Then, PI-3 kinase phosphorylates and activates Akt, some of whose targets have been proposed to play a role in the regulation of cell survival, including glycogen synthase kinase (GSK)-3ß, Bcl-2 antagonist of cell death (BAD), forkhead transcription factors, and caspase-9.30 31 32 33 Although NMDA has been reported to prolong the survival and outgrowth of developing cerebellar granule cell neurons,34 this type of prosurvival event has not been studied in detail in RGCs. In addition, to date, there have been no studies of the PI-3 kinase-Akt pathway in the retina exposed to NMDA.
In this study, we show that NMDA causes neuronal death after activating and phosphorylating p38 in rat retinas in vivo. However, NMDA also activates Akt. We demonstrate that the p38 pathway is proapoptotic and the PI-3 kinase-Akt pathway is antiapoptotic for RGCs.
| Materials and Methods |
|---|
|
|
|---|
Retrograde Labeling of RGCs
Adult male Long-Evans rats weighing 200 to 250 g were obtained from a local breeder and housed in a 12-hour lightdark cycle with access to food and water ad libitum. Animals were anesthetized with 1% to 2% isoflurane and 70% N2O for all experimental manipulations. Retrograde labeling was achieved by injection of 5% aminostilbamidine (FluoroGold; Molecular Probes, Eugene, OR) into the superior colliculus to allow quantification of cell bodies, as previously described.22 35 36
Drug Application
Four days after the injection of aminostilbamidine, intravitreous injections were performed with a 33-gauge needle attached to a 5-µL syringe (MS NE05; Ito Corp., Fuji, Japan) after pupil dilation with 1% atropine sulfate. Hydroxyethyl cellulose (Scopisol 15; Senju Pharmaceutical Co. Ltd., Osaka, Japan) was dropped onto the cornea, and a small cover glass was placed for intraocular visualization under stereomicroscopy. The tip of the needle was inserted into the vitreous just above the retina through the dorsal limbus of the eye. Injections were completed over a period of 3 minutes. Intravitreous injections were performed with several doses of NMDA and 10 nmol glycine, with SB203580 (Calbiochem, San Diego, CA), LY294002 (Calbiochem), or control solutions (an equal volume of dimethyl sulfoxide [DMSO]). Any animal with visible lens damage and/or vitreous hemorrhage was not included in the analysis.
Quantification of RGC Survival
At various time points, rats were killed with an overdose of pentobarbital, and the eyes were removed. Eyecups were prepared by removing anterior segments in phosphate-buffered saline (PBS) solution and fixed in a 4% paraformaldehyde solution for 20 minutes. Then the retina was carefully dissected from the eye, prepared as a flatmount in PBS solution, mounted on glass slides, and examined by epifluorescence microscopy to visualize RGCs. The number of surviving RGCs in experimental and control retinas was determined by counting aminostilbamidine-labeled neurons in three standard areas of each retinal quadrant at one sixth, one half, and five sixths of the retinal radius, for a total area of 2.25 mm2, as previously described by Kikuchi et al.22 RGC survival for each group of animals was assessed from the mean density (RGCs/mm2) ± SEM for three to nine retinas.
Immunohistochemistry
After enucleation, the eyes were immersed overnight in fixative composed of 4% paraformaldehyde in PBS (pH 7.4) at 4°C, followed by cryoprotection by soaking in 30% sucrose overnight at 4°C. Eyes were frozen in optimal cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetechnical Co., Ltd., Tokyo, Japan) on dry ice, and 8-µm-thick cryostat sections were cut, thaw mounted onto glass slides coated with poly-L-lysine, and air dried overnight at 4°C. Sections were treated for 15 minutes at room temperature with Tris-buffered saline (pH 7.4, TBS) containing 0.1% Triton X-100 (TBST) to increase membrane permeability, followed by 0.3% hydrogen peroxide for 10 minutes to block intrinsic peroxidase activity. After they were rinsed, sections were incubated with TBS containing 10% normal goat serum (NGS) for 1 hour. Sections were incubated overnight at 4°C in TBS with 10% NGS and either 1:100 anti-phospho-p38 (Thr180/Tyr182) or 1:200 anti-phospho-Akt (Ser 473; imunohistochemistry-specific). The sections were then incubated in TBS with 10% NGS and 1:100 biotinylated anti-rabbit IgG (Vector Laboratories, Inc., Burlingame, CA) at room temperature for 1 hour. After another rinse, the sections were incubated in avidin-biotin complex (ABC) reagent (Vectastain ABC Kit; Vector Laboratories, Inc.) at room temperature for 30 minutes, according to the manufacturers instructions. Color development was performed with diaminobenzidine. Finally, counterstaining was performed with 1% methyl green.
For double-staining of phospho-p38 and phospho-Akt, sections were incubated with 1:100 mouse anti-phospho-p38 antibody and 1:100 rabbit anti-phospho-Akt antibody overnight at 4°C. The sections were then incubated in TBS with 10% NGS, 1:200 anti-mouse IgG (Alexa Fluor 594), 1:200 anti-rabbit IgG (Alexa Fluor 488), and 2 µM 4',6-diamidino-2-phenylindole (DAPI; all from Molecular Probes) at room temperature for 1 hour. Finally, sections were washed three times in 10 mM PBS, exposed to 1 drop of anti-fade solution (Gel/Mount; Biomeda Corp., Foster City, CA), mounted on glass coverslips, and visualized with epifluorescence microscopy.
TUNEL Staining
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) staining was performed with a fluorescein apoptosis detection system (Promega Corp., Madison, WI), according to the manufacturers instructions. In brief, after cryosections were rinsed in PBS and reacted with 20 µg/mL proteinase K for 10 minutes at room temperature, they were incubated with terminal dUTP transferase enzyme and a mix of nucleotides in equilibration buffer for 60 minutes at 37°C in a moist chamber. After termination of the reaction by immersing in 2x SSC for 15 minutes, the samples were washed three times with PBS for 5 minutes each. For nuclear staining, samples were incubated in 2 µM DAPI solution for 5 minutes.
Immunoblot Analysis
Retinas were homogenized in buffer containing 10 mM HEPES, 2 mM EDTA, 0.1% 3-([3-cholamidopropyl]dimethylammonio-2-hydroxy-1-propanesulfonate (CHAPS), 5 mM dithiothreitol (DTT), 0.35 mg/mL phenylmethylsulfonyl fluoride (PMSF), 10 µg/mL pepstatin A, 10 µg/mL aprotinin, 20 µg/mL of leupeptin, and 10 mM sodium orthovanadate (pH 7.2), and centrifuged. The supernatant was collected, and the samples were used immediately or stored at -80°C before use. Protein concentrations were measured with a BCA protein assay reagent kit (Pierce, Rockford, IL), with albumin used as the standard. Aliquots containing 50 µg protein were added to 4x SDS sample buffer (NuPAGE; Invitrogen, Carlsbad, CA), boiled for 10 minutes, separated, and then transferred onto a nitrocellulose membrane (Hybond ECL; Amersham Pharmacia Biotech Inc., Piscataway, NJ). The membranes were blocked with TBST containing 10% NGS for 2 hours at room temperature and probed with the following antibodies: 1:1000 anti-p38, 1:1000 anti-phospho-p38, 1:1000 anti-Akt, or 1:1000 anti-phospho-Akt (Ser473). After rinsing with TBST, membranes were incubated in TBST containing 1:2000 horseradish peroxidase-linked anti-rabbit IgG for 1 hour at room temperature. Immunoblots were visualized with chemiluminescence detection (LumiGLO; Cell Signaling Technology). The intensity of each band was measured by densitometric analysis using image analysis software (NIH Image, ver. 1.61; NIH Image; W. Rasband, National Institutes of Health; available by ftp from zippy.nimh.nih.gov or on floppy disk from NTIS, Springfield, VA, catalog number PB95-500195GEI).
Kinase Activity Assay
We measured p38, Akt, and extracellular signal-regulated kinase (ERK) activities according to the instructions from relevant kits (Cell Signaling Technology) with slight modification. In brief, retinas were incubated in ice-cold cell lysis buffer plus 1 mM PMSF for 10 minutes, homogenized, and then centrifuged. The supernatant was collected, and the samples were used immediately or stored at -80°C before use. Protein concentrations were measured, and aliquots containing 150 µg protein were immunoprecipitated with anti-phospho-p38, anti-phospho-Akt, or anti-phospho-ERK immobilized antibodies. The immune complexes were collected by centrifugation and incubated for 30 minutes at 30°C in 50 µL kinase buffer supplemented with 200 µM adenosine triphosphate (ATP) and the corresponding substrate protein (2 µg activating transcription factor [ATF]-2 for p38, 1 µg GSK-3 for Akt, or 2 µg Elk-1 for ERK). The supernatant was transferred to a new tube containing 20 µL of 4x SDS sample buffer (NuPAGE, Invitrogen) and 4 µL of 1 M DTT to stop the reaction. Phospho-ATF-2, phospho-GSK3
/ß, or phospho-Elk-1 was detected by immunoblot analysis, and, as an index of kinase activity, the intensity of each band was determined by densitometric analysis. The relative activity of each sample was normalized to that of untreated samples for each experimental series.
Statistical Analysis
Statistical significance of the data was determined by an ANOVA followed by a post hoc Dunnett test.
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Injection of NMDA into the vitreous resulted in death that appeared to be apoptotic, because dying RGCs became pyknotic. Furthermore, our findings with TUNEL staining supported this notion and are consistent with previous reports.37 The distribution of TUNEL-positive cells varied temporally and spatially. We speculate that regional differences in retinal thickness may account for this phenomenon.
Within 1 day of injection of 20 nmol NMDA, more than 80% of the RGCs died, and little additional damage was observed after 200 nmol of NMDA. In contrast, 2 nmol NMDA did not cause significant cell death. After 10 nmol NMDA, approximately 50% of the RGCs died. These results are similar to the results in a previous report5 and show that 10 nmol NMDA causes reproducible but subtotal death of RGCs.
We detected p38 phosphorylation after exposure to 10 nmol or more NMDA with glycine. Phosphorylation of p38 was detected within 1 hour of injection of an excitotoxin and continued for 24 hours, whereas TUNEL-positive cells began to appear at 6 hours. This temporal difference indicates that activation of p38 preceded apoptosis. It interested us that p38 was phosphorylated only after lethal doses of NMDA, consistent with the notion that p38 is involved in a death-promoting pathway. In further support of this hypothesis, SB203580, a p38 inhibitor, partially protected RGCs from NMDA-induced death. The effective dose of 0.2 nmol SB203580 corresponds to a concentration of 1.6 µM in the vitreous (the volume of rat vitreous is
120 µL).40 At 1 to 2 µM, SB203580 has been reported to be relatively specific for p38.41 In fact, in our studies this concentration of SB203580 inhibited p38 MAP kinase activity both significantly and specifically, in that in control experiments it did not affect Akt or ERK activity. Taking all findings together, we suggest that the protective effect of SB203580 on RGCs is caused by inhibition of p38, although we acknowledge that another mode of action of the drug cannot be completely eliminated.
Similar to p38, we also found that NMDA-glycine induced phosphorylation and activation of Akt. However, even sublethal doses of NMDA (2 nmol) produced significant phosphorylation of Akt. In fact, a slight increase in phosphorylation of Akt was observed after injection of glycine alone in the absence of NMDA. Recently, a novel type of NMDA receptor was cloned that responds to glycine alone,42 and it is possible that this receptor or the conventional inhibitory glycine receptor was involved in this response. Alternatively, the injection into the vitreous itself, with consequent osmotic and inflammatory changes, could have triggered the increase in Akt phosphorylation. Whatever the reason, however, the degree of phosphorylation of Akt in the absence of injected NMDA (onefold increase) was slight compared with the effect of NMDA (fivefold increase).
To investigate whether activation of the PI-3 kinaseAkt pathway is involved in RGC survival, we administered the PI-3 kinase inhibitor LY294002 to eyes injected with NMDA. LY294002 appeared to inhibit the activity of Akt both significantly and specifically at the concentration used in our studies, in that it did not affect the activity of p38 or ERK in control experiments. Simultaneous administration of 6 nmol LY294002 (corresponding to 50 µM in the vitreous) enhanced RGC death in retinas injected with 10 nmol NMDA. Furthermore, unlike SB203580, a second administration of LY294002 had an additional detrimental effect on RGC survival after injection with 10 nmol NMDA. However, LY294002 did not increase RGC death due to 200 nmol NMDA, although a ceiling effect may have been reached, with 85% of the RGCs dying under these conditions. The results with LY294002 and 10 nmol NMDA suggest that the PI-3 kinase-Akt pathway is antiapoptotic in RGCs.
Recently, memantine, an uncompetitive open-channel blocker of the NMDA receptor, has entered advanced clinical trials for treatment of neurodegenerative diseases, including glaucoma.43 44 45 46 However, blockade of the NMDA receptor may inhibit neuroprotective pathways (e.g., Akt) as well as death-promoting pathways (e.g., p38), because we showed that at least some cells displayed activation of both Akt and p38 after exposure to an excitotoxin. Additional effectiveness could be gained by blocking only the proapoptotic pathways or by enhancing the antiapoptotic pathways in some other manner.
In conclusion, we show that the p38 MAP kinase and PI-3 kinaseAkt pathways are both activated after stimulation of NMDA receptors in the retina in vivo. Our inhibitor studies suggest that the p38 MAP kinase pathway is proapoptotic, whereas the PI-3 kinaseAkt pathway is antiapoptotic in RGCs. The elucidation of these divergent signaling pathways after stimulation of NMDA receptors may lead to more effective strategies for treating neurodegenerative diseases, including glaucoma, retinal ischemic disease, and optic neuropathy, in that excessive activity of NMDA receptors has been linked to these ophthalmic disorders.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication February 25, 2002; revised July 10, 2002; accepted July 19, 2002.
Commercial relationships policy: F, C, P.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Stuart A. Lipton, Center for Neuroscience and Aging, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037; slipton{at}burnham.org.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. W. Hein, Y. Ren, Z. Yuan, W. Xu, S. Somvanshi, T. Nagaoka, A. Yoshida, and L. Kuo Functional and Molecular Characterization of the Endothelin System in Retinal Arterioles Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3329 - 3336. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lebrun-Julien, L. Duplan, V. Pernet, I. Osswald, P. Sapieha, P. Bourgeois, K. Dickson, D. Bowie, P. A. Barker, and A. Di Polo Excitotoxic Death of Retinal Neurons In Vivo Occurs via a Non-Cell-Autonomous Mechanism J. Neurosci., April 29, 2009; 29(17): 5536 - 5545. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nakanishi, S. Tu, Y. Shin, J. Cui, T. Kurokawa, D. Zhang, H.-S. V. Chen, G. Tong, and S. A. Lipton Neuroprotection by the NR3A Subunit of the NMDA Receptor J. Neurosci., April 22, 2009; 29(16): 5260 - 5265. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Yang, J. Lafleur, B. R. Mwaikambo, T. Zhu, C. Gagnon, S. Chemtob, A. Di Polo, and P. Hardy The Role of Lysophosphatidic Acid Receptor (LPA1) in the Oxygen-Induced Retinal Ganglion Cell Degeneration Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1290 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Biswas, Y. Zhao, A. Nagalingam, T. W. Gardner, and L. Sandirasegarane PDGF- and Insulin/IGF-1-Specific Distinct Modes of Class IA PI 3-Kinase Activation in Normal Rat Retinas and RGC-5 Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3687 - 3698. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Levkovitch-Verbin, R. Dardik, S. Vander, Y. Nisgav, M. Kalev-Landoy, and S. Melamed Experimental glaucoma and optic nerve transection induce simultaneous upregulation of proapoptotic and prosurvival genes. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2491 - 2497. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. El-Remessy, M. Al-Shabrawey, Y. Khalifa, N.-T. Tsai, R. B. Caldwell, and G. I. Liou Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes Am. J. Pathol., January 1, 2006; 168(1): 235 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Harada, K. Nakamura, K. Namekata, A. Okumura, Y. Mitamura, Y. Iizuka, K. Kashiwagi, K. Yoshida, S. Ohno, A. Matsuzawa, et al. Role of Apoptosis Signal-Regulating Kinase 1 in Stress-Induced Neural Cell Apoptosis in Vivo Am. J. Pathol., January 1, 2006; 168(1): 261 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Manabe, Z. Gu, and S. A. Lipton Activation of Matrix Metalloproteinase-9 via Neuronal Nitric Oxide Synthase Contributes to NMDA-Induced Retinal Ganglion Cell Death Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4747 - 4753. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Mali, M. Cheng, and S. K. Chintala Plasminogen activators promote excitotoxicity-induced retinal damage FASEB J, August 1, 2005; 19(10): 1280 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cao, J. I. Viholainen, C. Dart, H. K. Warwick, M. L. Leyland, and M. J. Courtney The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death J. Cell Biol., January 3, 2005; 168(1): 117 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, M. Cheng, and S. K. Chintala Kainic Acid-Mediated Upregulation of Matrix Metalloproteinase-9 Promotes Retinal Degeneration Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2374 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Weishaupt, G. Rohde, E. Polking, A.-L. Siren, H. Ehrenreich, and M. Bahr Effect of Erythropoietin Axotomy-Induced Apoptosis in Rat Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1514 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Danias, K. C. Lee, M.-F. Zamora, B. Chen, F. Shen, T. Filippopoulos, Y. Su, D. Goldblum, S. M. Podos, and T. Mittag Quantitative Analysis of Retinal Ganglion Cell (RGC) Loss in Aging DBA/2NNia Glaucomatous Mice: Comparison with RGC Loss in Aging C57/BL6 Mice Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5151 - 5162. [Abstract] [Full Text] |
||||
![]() |
S. Roth, A. R. Shaikh, M. M. Hennelly, Q. Li, V. Bindokas, and C. E. Graham Mitogen-Activated Protein Kinases and Retinal Ischemia Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5383 - 5395. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |